OverviewSuggest Edit

Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt intends to develop Episalvan as a new treatment for a hereditary skin disorder called Epidermolysis Bullosa in both Europe and the U.S. Amryt’s earlier stage products are focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is high unmet medical needs. These include acromegaly and Cushing's disease.

TypePublic
Founded2004
HQGreater London, GB
Websiteamrytpharma.com

Latest Updates

Employees (est.) (Jul 2016)4
Revenue (FY, 2018)£12.9 M(+14%)
Share Price (Oct 2017)£0.2

Key People/Management at Amryt Pharma

Joe Wiley

Joe Wiley

Chief Executive Officer (CEO)
Mark Sumeray

Mark Sumeray

Chief Medical Officer (CMO)
David Allmond

David Allmond

Chief Commercial Officer (CCO)
Stephen Joyce

Stephen Joyce

VP, Global Marketing
Ray Stafford

Ray Stafford

Non-Executive Chairman
Stephen Wills

Stephen Wills

Non-Executive Director
Show more

Amryt Pharma Office Locations

Amryt Pharma has offices in Greater London, Boston, Niefern-Öschelbronn and Dublin
Greater London, GB (HQ)
1 Adam St
Niefern-Öschelbronn, DE
Streiflingsweg 11
Dublin, IE
90 Harcourt St, Saint Kevin's
Boston, US
53 State St #500
Show all (4)

Amryt Pharma Financials and Metrics

Amryt Pharma Revenue

Embed Graph
View revenue for all periods
Amryt Pharma's revenue was reported to be £12.89 m in FY, 2018
GBP

Revenue (FY, 2018)

12.9m

Gross profit (FY, 2018)

8.2m

Gross profit margin (FY, 2018), %

63.3%

Net income (FY, 2018)

(23.0m)

EBIT (FY, 2018)

(13.6m)

Market capitalization (31-Oct-2017)

40.4m

Closing stock price (31-Oct-2017)

0.2

Cash (31-Dec-2018)

8.7m

EV

83.3m
Amryt Pharma's current market capitalization is £40.4 m.
GBPFY, 2016FY, 2017FY, 2018

Revenue

1.2m11.4m12.9m

Cost of goods sold

522.1k4.8m4.7m

Gross profit

681.6k6.6m8.2m

Gross profit Margin, %

57%58%63%
GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash

12.5m7.4m18.3m8.7m

Accounts Receivable

752.0k2.6m2.8m

Inventories

686.0k965.5k1.7m

Current Assets

12.6m10.3m23.5m15.0m
GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash From Operating Activities

(2.8m)(5.4m)(10.6m)(11.6m)

Cash From Investing Activities

2.3m2.2m(281.7k)(189.0k)

Cash From Financing Activities

10.5m21.7m2.5m

Net Change in Cash

(477.1k)7.2m10.8m(9.4m)
GBPY, 2018

EV/EBIT

-6.1 x

EV/CFO

-7.2 x

Financial Leverage

-21.9 x
Show all financial metrics

Amryt Pharma Online and Social Media Presence

Embed Graph

Amryt Pharma News and Updates

UK's Amryt Pharma unites lomitapide franchise with Aegerion deal

Britain's Amryt Pharma has agreed to buy Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, in a deal that reunites the franchise for lomitapide, a treatment for patients with a rare cholesterol disorder.

Novelion Therapeutics Announces Subsidiary Aegerion Pharmaceuticals to Recapitalize Through Court Supervised Process In Which Amryt Pharma Plc Will Acquire 100% of Reorganized Stock of Aegerion

VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (Novelion), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that its wholly-owned subsid…

Amryt Pharma plc: Lojuxta to be reimbursed in France

17 October 2018 AIM: AMYT ESM: AYP

Amryt Pharma Frequently Asked Questions

  • When was Amryt Pharma founded?

    Amryt Pharma was founded in 2004.

  • Who are Amryt Pharma key executives?

    Amryt Pharma's key executives are Joe Wiley, Mark Sumeray and David Allmond.

  • How many employees does Amryt Pharma have?

    Amryt Pharma has 4 employees.

  • What is Amryt Pharma revenue?

    Latest Amryt Pharma annual revenue is £12.9 m.

  • What is Amryt Pharma revenue per employee?

    Latest Amryt Pharma revenue per employee is £3.2 m.

  • Who are Amryt Pharma competitors?

    Competitors of Amryt Pharma include GT Biopharma, Radius Health and PTC Therapeutics.

  • Where is Amryt Pharma headquarters?

    Amryt Pharma headquarters is located at 1 Adam St, Greater London.

  • Where are Amryt Pharma offices?

    Amryt Pharma has offices in Greater London, Boston, Niefern-Öschelbronn and Dublin.

  • How many offices does Amryt Pharma have?

    Amryt Pharma has 4 offices.